Skip to main
TVTX
TVTX logo

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 56%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics Inc. is experiencing robust growth in its Filspari product, with a 37% quarter-over-quarter increase in new patient start forms predicted for 4Q24, signaling strong market acceptance. The company's revised total net sales projection for 2025 has increased to $339.9 million, driven by anticipated regulatory events and expanding market opportunities for both focal segmental glomerulosclerosis and IgA nephropathy. Additionally, with anticipated peak revenue from Filspari projected to reach $975.9 million by 2033, complemented by a growing royalty revenue stream from European markets, Travere Therapeutics is positioned favorably within the biopharmaceutical sector.

Bears say

Travere Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from potential regulatory hurdles and market dynamics. The company is at risk due to the possibility of failing to secure regulatory approval for its candidate pegtibatinase and encountering clinical trial failures, while the commercial opportunity for its product FILSPARI may be limited by competition and pricing issues. Furthermore, the recent announcement of a voluntary enrollment pause in the HARMONY study to address manufacturing scale-up, combined with potential competitive pressures, raises concerns over the company's ability to meet financial forecasts and adequately sustain operations.

Travere Therapeutics (TVTX) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 56% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 16 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.